Evidence mapPaperPMID 41522193Full record

ReviewAutophagy reports2026

Glycophagy: molecular mechanisms, regulatory signals, and disease associations.

Lei Chen, Jinyong Jiang, Meiqing Liu, Linxi Chen

Abstract readReview
In one paragraph

Review in Autophagy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Contradictory Effects on Hepatocytes in ASMD.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lei ChenInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, China.
Jinyong JiangDepartment of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou, China.
Meiqing LiuYan'an Hospital Affiliated to Kunming Medical University, Central Laboratory, Kunming, China.
Linxi ChenInstitute of Pharmacy and Pharmacology, University of South China, Hengyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycophagy is a process of selective degradation of glycogen through the autophagy pathway. It relies on key proteins, such as STBD1 (glycogen-specific autophagy receptor), GABARAPL1 (member of the ATG8 family), and acid α-glucosidase (GAA), and proceeds through the steps of "glycogen recognition - autophagosome encapsulation - lysosomal degradation" to release glucose, thereby maintaining energy homeostasis. This process is regulated by multiple signaling pathways, such as AMPK, mTOR, CAMP/PKA, and calcium signaling pathways, which jointly respond to cellular energy demands and metabolic states. Glycophagy occurs under conditions, such as starvation, exercise, and energy metabolism disorders, and plays a role in diseases with glycogen metabolism disorders. Its functions include energy supply, blood sugar regulation, maintenance of cellular homeostasis, and influencing cellular aging. Dysfunction of glycophagy can lead to various diseases, such as glycogen storage diseases and diabetic cardiomyopathy. In-depth study of the regulatory mechanisms of glycophagy is helpful for developing therapeutic strategies for related diseases.

Indexed as

autophagy regulationGABARAPL1Glycophagymetabolic disordersSTBD1

Identifiers

PMID41522193
PMCPMC12785236

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.